書籍情報から探す
MOLECULAR-TARGETED THERAPY MAY BENEFIT JAPANESE RENAL-CELL CARCINOMA PATIENTS WHO HAVE MEMORIAL SLOAN KETTERING CANCER CENTER INTERMEDIATE-RISK CLASSIFICATION : A MULTI-INSTITUTIONAL COOPERATIVE STUDY
TOMOYUKI SHIMABUKURO1), KAZUHIRO NAGAO2), HIDEYASU MATSUYAMA2), SHIGERU SAKANO3), NORIO YAMAMOTO4), TAKAHITO NASU5), MITSUTAKA YAMAMOTO6), KIMIO TAKAI7), SATORU YOSHIHIRO8), KAZUO OBA9)
1)Department of Urology, Ube Industries Central Hospital, 2)Department of Urology, Yamaguchi University Graduate School of Medicine, 3)Department of Urology, Kokura Memorial Hospital, 4)Department of Urology, Tokuyama Medical Association Hospital, 5)Department of Urology and Nephrology, Tokuyama Central Hospital, 6)Department of Urology, Yamaguchi Grand Medical Center, 7)Department of Urology, Saiseikai Shimonoseki General Hospital, 8)Department of Urology, Shimonoseki City Hospital, 9)Department of Urology, Saiseikai Yamaguchi General Hospital
Nishinihon Journal of Urology 77 (12) 436-445, 2015.
1)Department of Urology, Ube Industries Central Hospital, 2)Department of Urology, Yamaguchi University Graduate School of Medicine, 3)Department of Urology, Kokura Memorial Hospital, 4)Department of Urology, Tokuyama Medical Association Hospital, 5)Department of Urology and Nephrology, Tokuyama Central Hospital, 6)Department of Urology, Yamaguchi Grand Medical Center, 7)Department of Urology, Saiseikai Shimonoseki General Hospital, 8)Department of Urology, Shimonoseki City Hospital, 9)Department of Urology, Saiseikai Yamaguchi General Hospital
Nishinihon Journal of Urology 77 (12) 436-445, 2015.
- アブストラクト: 従量制は110円(税込)、基本料金制は基本料金に含まれます。
- 全文ダウンロード: 従量制、基本料金制の方共に770円(税込) です。